Advertisement
Advertisement
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
2.96
USDSponsored
-0.05
-1.66%
Jul 24, 15:59 UTC -4
Closed
After-Market
2.96
0.00
+0.17%
RXRX Earnings Reports
Positive Surprise Ratio
RXRX beat 13 of 20 last estimates.
65%
Next Report
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$12.19M
/-$0.23
Implied change from Q1 26 (Revenue/ EPS)
+88.28%
/+4.55%
Implied change from Q2 25 (Revenue/ EPS)
-36.61%
/-43.90%
Recursion Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue
On May 06, 2026, RXRX reported earnings of -0.22 USD per share (EPS) for Q1 26, beating the estimate of -0.27 USD, resulting in a 20.55% surprise. Revenue reached 6.47 million, compared to an expected 16.09 million, with a -59.78% difference. The market reacted with a +1.78% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.23 USD, with revenue projected to reach 12.19 million USD, implying an increase of 4.55% EPS, and increase of 88.28% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NovoCure Limited Ordinary Shares
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+61.70%
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
argenx SE - ADR
Report Date
Jul 23, 2026 For Q2 26
Estimate
$6.29
Actual
$7.32
Surprise
+16.38%
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
What were Recursion Pharmaceuticals, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Recursion Pharmaceuticals, Inc. Class A Common Stock reported EPS of -$0.22, beating estimates by 20.55%, and revenue of $6.47M, -59.78% below expectations.
How did the market react to Recursion Pharmaceuticals, Inc. Class A Common Stock's Q1 2026 earnings?
The stock price moved up 1.78%, changed from $3.37 before the earnings release to $3.43 the day after.
When is Recursion Pharmaceuticals, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Recursion Pharmaceuticals, Inc. Class A Common Stock's next earnings report?
Based on 7
analysts, Recursion Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of -$0.23 and revenue of $12.19M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement